Astrazeneca Ab

Astra Zeneca U.k. Limited

Astra Pharmaeuticals Ltd.

David Cladingboel

Michael P Mortimore

David R Cheshire

Thomas McInally

Andrew Baxter

Michael Stocks

Annika Björe

Gert Strandlund

John Pavey

Colin Thomson

Simon Hirst

Carol Manners

Adam Herring

Lal Cheema

Peder Svensson

David Hardern

Kurt-Jürgen Hoffmann

Fritiof Pontén

Johan Kajanus

Magnus Björsne

Karin Lövqvist

Michael Wilsterman

Carl-Gustav Sigfridsson

Christina Olsson

Gareth Ensor

Robert Lundqvist

Neil Barnwell

Rhona Sinclair

There is provided compounds of formula I, wherein R, R, R, Rto R, X, Y and Z have meanings given in the description, which compounds are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.

Oxabispidine compounds for the treatment of cardiac arrhythmias

There is provided compounds of formula I, wherein R, R, R, R, Rto R, A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.

Oxabispidine compounds useful in the treatment of cardiac arrhythmias

Compounds of Formula I, wherein Rrepresents Calkyl (optionally substituted by one or more substituents selected from &#x2014;OH, halo, cyano, nitro and aryl) or aryl, wherein each aryl and aryloxy group, unless otherwise specified, is optionally substituted, and methods of preparation thereof are disclosed 

Chemical intermediate

There is provided substantially crystalline forms of 4-({3-[7-(3,3-dimethyl-2-oxobutyl) -9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]propyl}amino)benzo-nitrile; tert-butyl 2 -{7-[3-(4-cyanoanilino)propyl]-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl}ethylcarbamate; tert-butyl 2-{7-[4-(4-cyanophenyl)butyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}ethylcarbamate; or tert-butyl 2-{7-[2S)-3-(4-cyanophenoxy)-2-hydroxypropyl]-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl}ethylcarbamate and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of cardiac arhythmias.

3,7-Diazabicyclo [3.3.1] formulations as anti-arrhythmic compounds

There is provided a process for the preparation of a compound of formula (I): which process comprises reaction of a compound of formula (II): with either a compound of formula (III): or acrylamide, followed, in the latter case, by reaction of the resulting intermediate of formula (IV): with an alcohol of formula R&#x2014;OH and an agent that promotes, or agents that in combination promote, rearrangement and oxidation of the compound of formula IV to an intermediate isocyanate, which may then react with the alcohol of formula R&#x2014;OH, and wherein R, Rand Rhave meanings given in the description 

Process for the preparation of oxabispidines

The invention provides adamantane derivatives, a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy.

Compounds

The invention relates to novel pyridyl derivatives, their use as medicaments, pharmaceutical formulations containing them and methods for their preparation.

Pyridine derivatives and pharmaceutical compositions containing them

The invention relates to novel pyridyl derivatives, their use as medicaments, pharmaceutical formulations including them and methods for their preparation.

Adamantane derivatives

Growing community of inventors

Loughborough, United Kingdom

David Cladingboel